(S)-1-((S)-2-{[1-(4-amino-3-chloro-phenyl)-methanoyl]-amino}-3,3-dimethyl-butanoyl)-pyrrolidine-2-carboxylic acid ((2R,3S)-2-ethoxy-5-oxo-tetrahydro-furan-3-yl)-amide (VX-765), an orally available selective interleukin (IL)-converting enzyme/caspase-1 inhibitor, exhibits potent anti-inflammatory activities by inhibiting the release of IL-1β and IL-18

被引:237
|
作者
Wannamaker, Woods
Davies, Robert
Namchuk, Mark
Pollard, John
Ford, Pamella
Ku, George
Decker, Caroline
Charifson, Paul
Weber, Peter
Germann, Ursula A.
Kuida, Keisuke
Randle, John C. R. [1 ]
机构
[1] Vertex Pharmaceut Inc, Dept Chem, Cambridge, MA USA
[2] Vertex Pharmaceut Inc, Dept Prot Sci, Cambridge, MA USA
[3] Vertex Pharmaceut Inc, Dept Biol, Cambridge, MA USA
[4] Vertex Pharmaceut Inc, Drug Discovery Support Unit, Cambridge, MA USA
[5] Vertex Pharmaceut Inc, Dept Modeling, Cambridge, MA USA
[6] Vertex Pharmaceut Inc, Strateg Dev, Cambridge, MA USA
来源
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS | 2007年 / 321卷 / 02期
关键词
D O I
10.1124/jpet.106.111344
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
S)- 1-(( S)- 2-{[ 1-( 4- Amino- 3- chloro- phenyl)- methanoyl]- amino}3,3- dimethyl- butanoyl)- pyrrolidine- 2- carboxylic acid (( 2R, 3S)- 2ethoxy- 5- oxo- tetrahydro- furan- 3- yl)- amide ( VX- 765) is an orally absorbed prodrug of ( S)- 3-({1-[( S)- 1-(( S)- 2-{[ 1-( 4- amino- 3- chlorophenyl)methanoyl]- amino}- 3,3- dimethyl- butanoyl)- pyrrolidin- 2yl]- methanoyl}- amino)- 4- oxo- butyric acid ( VRT- 043198), a potent and selective inhibitor of interleukin- converting enzyme/ caspase- 1 subfamily caspases. VRT- 043198 exhibits 100- to 10,000- fold selectivity against other caspase- 3 and - 6 to - 9. The therapeutic potential of VX- 765 was assessed by determining the effects of VRT- 043198 on cytokine release by monocytes in vitro and of orally administered VX- 765 in several animal models in vivo. In cultures of peripheral blood mononuclear cells and whole blood from healthy subjects stimulated with bacterial products, VRT043198 inhibited the release of interleukin ( IL)- 1 beta and IL-18, but it had little effect on the release of several other cytokines, including IL-1 alpha, tumor necrosis factor-alpha, IL-6 and IL-8. In contrast, VRT-043198 had little or no demonstrable activity in cellular models of apoptosis, and it did not affect the proliferation of activated primary T cells or T- cell lines. VX-765 was efficiently converted to VRT-043198 when administered orally to mice, and it inhibited lipopolysaccharide- induced cytokine secretion. In addition, VX765 reduced disease severity and the expression of inflammatory mediators in models of rheumatoid arthritis and skin inflammation. These data suggest that VX-765 is a novel cytokine inhibitor useful for treatment of inflammatory diseases.
引用
收藏
页码:509 / 516
页数:8
相关论文
共 2 条
  • [1] Characterization of (2R, 3S)-2-({[4-(2-butynyloxy)phenyl] sulfony1}amino)-N,3-dihydroxybutanamide, a potent and selective inhibitor of TNF-α converting enzyme
    Zhang, YH
    Hegen, M
    Xu, J
    Keith, JC
    Jin, GX
    Du, XM
    Cummons, T
    Sheppard, BJ
    Sun, LH
    Zhu, Y
    Rao, VR
    Wang, Q
    Xu, WX
    Cowling, R
    Nickerson-Nutter, CL
    Gibbons, J
    Skotnicki, J
    Lin, LL
    Levin, J
    INTERNATIONAL IMMUNOPHARMACOLOGY, 2004, 4 (14) : 1845 - 1857
  • [2] Characterization of (2S,4R)-1-[5-chloro-1-[(2,4-dimethoxyphenyl)sulfonyl]-3-(2-methoxy-phenyl)-2-oxo-2,3-dihydro-1H-indol-3-yl]-4-hydroxy-N,N-dimethyl-2-pyrrolidine carboxamide (SSR149415), a selective and orally active vasopressin V1b receptor antagonist
    Serradeil-Le Gal, C
    Wagnon, J
    Simiand, J
    Griebel, G
    Lacour, C
    Guillon, G
    Barberis, C
    Brossard, G
    Soubrié, P
    Nisato, D
    Pascal, M
    Pruss, R
    Scatton, B
    Maffrand, JP
    Le Fur, G
    JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2002, 300 (03): : 1122 - 1130